"The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and usually non-cancerous tumor.
GCTB generally occurs in a"...
- Patient Information:
Details with Side Effects
Rescula (unoprostone isopropyl) Ophthalmic Solution 0.15% is indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
DOSAGE AND ADMINISTRATION
The recommended dosage is one drop in the affected eye(s) twice daily.
Rescula may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If two drugs are used, they should be administered at least five (5) minutes apart [see PATIENT INFORMATION].
Dosage Forms And Strengths
Unoprostone isopropyl ophthalmic solution 1.5 mg/mL.
Storage And Handling
Rescula (unoprostone isopropyl) Ophthalmic Solution 0.15% is supplied sterile in a low-density polyethylene bottle with a low-density polyethylene dropper tip, a turquoise polypropylene closure, and a clear tamper-evident shrinkband.
5 mL in a 7.5 mL bottle NDC 17350-015-05
Store between 2° - 25°C (36° - 77°F).
Marketed by: Sucampo Pharma Americas, LLC, Bethesda, MD 20814
Last reviewed on RxList: 1/3/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Rescula Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.